Oral delivery of insulin may significantly improve the quality of life of diabetes patients who routinely receive insulin by the subcutaneous route. In fact, compared with this administration route, oral delivery of insulin in diabetes treatment offers many advantages: Higher patient compliance, rapid hepatic insulinization, and avoidance of peripheral hyperinsulinemia and other adverse effects such as possible hypoglycemia and weight gain. However, the oral delivery of insulin remains a challenge because its oral absorption is limited. The main barriers faced by insulin in the gastrointestinal tract are degradation by proteolytic enzymes and lack of transport across the intestinal epithelium. Several strategies to deliver insulin orally have been proposed, but without much clinical or commercial success. Protein encapsulation into nanoparticles is regarded as a promising alternative to administer insulin orally because they have the ability to promote insulin paracellular or transcellular transport across the intestinal mucosa. In this review, different delivery systems intended to increase the oral bioavailability of insulin will be discussed, with a special focus on nanoparticulate carrier systems, as well as the efforts that pharmaceutical companies are making to bring to the market the first oral delivery system of insulin. The toxicological and safety data of delivery systems, the clinical value and progress of oral insulin delivery, and the future prospects in this research field will be also scrutinized.
MeetooDMcGovernPSafadiR.An epidemiological overview of diabetes across the world. Br J Nurs.2007;16 (16): 1002–7.
2.
ReichardPNilssonBYRosenqvistU.The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med.1993;329 (5): 304–9.
3.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993;329 (14): 977–86.
4.
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA.2002;287 (19): 2563–9.
5.
SaaddineJBCadwellBGreggEWEngelgauMMVinicorFImperatoreGNarayanKM, Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med.2006;144 (7): 465–74.
6.
HeinemannLJacquesY.Oral insulin and buccal insulin: A critical reappraisal. J Diabetes Sci Technol.2009;3 (3): 568–84.
HoffmanAZivE.Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet.1997;33 (4): 285–301.
9.
OwensDR, New horizons–alternative routes for insulin therapy. Nat Rev Drug Discov.2002;1 (7): 529–40.
10.
KhafagyEl-SMorishitaMOnukiYTakayamaK.Current challenges in non-invasive insulin delivery systems: A comparative review. Adv Drug Deliv Rev.2007;59 (15): 1521–46.
11.
CarinoGPMathiowitzE.Oral insulin delivery. Adv Drug Deliv Rev.1999;35 (2–3): 249–57.
12.
HeinemannL.New ways of insulin delivery. Int J Clin PractSuppl.2011; (170): 31–46.
13.
WongTW, Design of oral insulin delivery systems. J Drug Target.2010;18 (2): 79–92.
14.
ChenMCSonajeKChenKJSungHW, A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials.2011;32 (36): 9826–38.
15.
KraulandAHGuggiDBernkop-SchnurchA.Oral insulin delivery: The potential of thiolated chitosan-insulin tablets on non-diabetic rats. J Control Release.2004;95 (3): 547–55.
16.
LiJYangLFergusonSMHudsonTJWatanabeSKatsumaMFixJA, In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES) in multi-pH media using United States Pharmacopeia apparatus II and III. AAPS PharmSciTech.2002;3 (4): E33.
17.
KatsumaMWatanabeSKawaiHTakemuraSSakoK.Effects of absorption promoters on insulin absorption through colon-targeted delivery. Int J Pharm.2006;307 (2): 156–62.
18.
HosnyEAAl-ShoraHIElmazarMM, Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: Effect on relative hypoglycemia of diabetic beagle dogs. Int J Pharm.2002;237 (1–2): 71–6.
19.
WhiteheadKShenZMitragotriS.Oral delivery of macromolecules using intestinal patches: Applications for insulin delivery. J Control Release.2004;98 (1): 37–45.
20.
GrabovacVFogerFBernkop-SchnurchA.Design and in vivo evaluation of a patch delivery system for insulin based on thiolated polymers. Int J Pharm.2008;348 (1–2): 169–74.
GehoWBGehoHCLauJRGanaTJ, Hepatic-directed vesicle insulin: A review of formulation development and preclinical evaluation. J Diabetes Sci Technol.2009;3 (6): 1451–9.
LuzioSDDunseathGLockettABroke-SmithTPNewRROwensDR, The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes Metab.2010;12 (1): 82–7.
33.
KidronMEldorRMitevaYFreierRArbitE.Extended exposure to an oral insulin formulation yields decreased insulin secretion in type II diabetes subjects. Presented at the Diabetes Technology Meeting, Bethesda, MD, November 11–13, 2010.
34.
EldorRArbitEMitevaYFreierRKidronM.Oral insulin: Type I diabetes (T1DM) patient response upon preprandial administration. Presented at the 70th American Diabetes Association Scientific Sessions, Orlando, FL, June 25–29, 2010.
35.
EldorRArbitEMitevaYKidronM.Evaluation of the safety and efficacy of two oral insulin formulations in healthy volunteers. Presented at the Diabetes Technology Meeting, San Francisco, CA, October 2011.
36.
YangSZhuJLuYLiangBYangC.Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res.1999;16 (5): 751–7.
37.
MüllerRHMäderKGohlaS.Solid lipid nanoparticles (SLN) for controlled drug delivery — A review of the state of the art. Eur J Pharm Biopharm.2000;50 (1): 161–77.
38.
MehnertWMäderK.Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev.2001;47 (2–3): 165–96.
39.
García-FuentesMTorresDAlonsoMJ, Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Coll Surf B Biointerf.2002;27: 159–68.
40.
SarmentoBMartinsSFerreiraDSoutoEB, Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomedicine.2007;2 (4): 743–9.
41.
ZhangNPingQHuangGXuWChengYHanX.Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm.2006;327 (1–2): 153–9.
42.
PatelHMRymanBE, Oral administration of insulin by encapsulation within liposomes. FEBS Lett.1976;62 (1): 60–3.
43.
AxtJSarrachDZipperJ.[Biopharmaceutical studies on phospholipid liposomes as carriers for the oral administration of insulin]. Pharmazie.1983;38 (4): 246–8.
44.
IwanagaKOnoSNariokaKMorimotoKKakemiMYamashitaSNangoMOkuN.Oral delivery of insulin by using surface coating liposomes: Improvement of stability of insulin in GI tract. Int J Pharm.1997;157 (1): 73–80.
45.
KiselMAKulikLNTsybovskyISVlasovAPVorob'yovMSKholodovaEAZabarovskayaZV, Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: Studies in the rat. Int J Pharm.2001;216 (1–2): 105–14.
TakeuchiHYamamotoHNiwaTHinoTKawashimaY.Mucoadhesion of polymer-coated liposomes to rat intestine in vitro. Chem Pharm Bull (Tokyo).1994;42 (9): 1954–6.
48.
TakeuchiHYamamotoHNiwaTHinoTKawashimaY.Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res.1996;13 (6): 896–901.
49.
TakeuchiHYamamotoHKawashimaY.Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev.2001;47 (1): 39–54.
50.
TakeuchiHMatsuiYYamamotoHKawashimaY.Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release.2003;86 (2–3): 235–42.
51.
DeğimITGümüŝelBDeğimZOzçelikayTTayAGünerS.Oral administration of liposomal insulin. J Nanosci Nanotechnol.2006;6 (9–10): 2945–9.
52.
DamgeCMichelCAprahamianMCouvreurP.New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes.1988;37 (2): 246–51.
53.
PanYZhengJMZhaoHYLiYJXuHWeiG.Relationship between drug effects and particle size of insulin-loaded bioadhesive microspheres. Acta Pharmacol Sin.2002;23 (11): 1051–6.
54.
JanesKACalvoPAlonsoMJ, Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev.2001;47 (1): 83–97.
55.
PanYLiYJZhaoHYZhengJMXuHWeiGHaoJSCuiFD, Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm.2002;249 (1–2): 139–47.
56.
SarmentoBRibeiroAVeigaFSampaioPNeufeldRFerreiraD.Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res.2007;24 (12): 2198–206.
57.
LinYHMiFLChenCTChangWCPengSFLiangHFSungHW, Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules.2007;8 (1): 146–52.
58.
MakhlofATozukaYTakeuchiH.Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci.2011;42 (5): 445–51.
59.
Van der MerweSMVerhoefJCVerheijdenJHKotzéAFJungingerHE, Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm.2004;58 (2): 225–35.
60.
QianFCuiFDingJTangCYinC.Chitosan graft copolymer nanoparticles for oral protein drug delivery: Preparation and characterization. Biomacromolecules.2006;7 (10): 2722–7.
61.
KotzeAFLuessenHLde LeeuwBJde BoerBGVerhoefJCJungingerHE, N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm Res.1997;14 (9): 1197–202.
62.
BayatADorkooshFADehpourARMoeziLLarijaniBJungingerHERafiee-TehraniM.Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm.2008;356 (1–2): 259–66.
63.
RekhaMRSharmaCP, Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J Control Release.2009;135 (2): 144–51.
64.
ReisCPRibeiroAJHoungSVeigaFNeufeldRJ, Nanoparticulate delivery system for insulin: Design, characterization and in vitro/in vivo bioactivity. Eur J Pharm Sci.2007;30 (5): 392–7.
65.
ZhangNLiJJiangWRenCLiJXinJLiK.Effective protection and controlled release of insulin by cationic beta-cyclodextrin polymers from alginate/chitosan nanoparticles. Int J Pharm.2010;393 (1–2): 212–8.
66.
SarmentoBRibeiroAVeigaFFerreiraDNeufeldR.Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules.2007;8 (10): 3054–60.
67.
ChalasaniKBRussell-JonesGJYandrapuSKDiwanPVJainSK, A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release.2007;117 (3): 421–9.
68.
ChalasaniKBRussell-JonesGJJainAKDiwanPVJainSK, Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release.2007;122 (2): 141–50.
69.
SarmentoBFerreiraDVasconcelosT.Polymer-based delivery systems for oral delivery of peptides and proteins. In: JorgensenLNielsenHM, eds. Delivery technologies for biopharmaceuticals: Peptides, proteins, nucleic acids and vaccines. Chichester: John Wiley & Sons; 2009, 207–26.
70.
SoppimathKSAminabhaviTMKulkarniARRudzinskiWE, Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release.2001;70 (1–2): 1–20.
71.
Des RieuxAFievezVGarinotMSchneiderYJPreatV.Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release.2006;116 (1): 1–27.
72.
PanyamJLabhasetwarV.Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev.2003;55 (3): 329–47.
73.
MundargiRCBabuVRRangaswamyVPatelPAminabhaviTM, Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release.2008;125 (3): 193–209.
74.
CsabaNGonzalezLSanchezAAlonsoMJ, Design and characterisation of new nanoparticulate polymer blends for drug delivery. J Biomater Sci Polym Ed.2004;15 (9): 1137–51.
75.
Alonso-SandeMDelgadoAEvoraCZoniouMRemuñán-LópezCAlonsoMJ, PLGA-mannosamine nanoparticles as new carriers for oral immunization. 2nd NanoSpain Workshop, Barcelona, Spain, March 14–17, 2005.
76.
CuiFDTaoAJCunDMZhangLQShiK.Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J Pharm Sci.2007;96 (2): 421–7.
77.
SunSLiangNPiaoHYamamotoHKawashimaYCuiF.Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: Formulation, characterization and in vivo evaluation. J Microencapsul.2010;27 (6): 471–8.
78.
XiongXYLiY PLiZLZhouCLTamKCLiuZYXieGX, Vesicles from Pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. J Control Release.2007;120 (1–2): 11–7.
79.
DamgeCMaincentPUbrichN.Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release.2007;117 (2): 163–70.
80.
DeutelBGreindlMThaurerMBernkop-SchnurchA.Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delivery system. Biomacromolecules.2008;9 (1): 278–85.
81.
VauthierCDubernetCFattalEPinto-AlphandaryHCouvreurP.Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev.2003;55 (4): 519–48.
82.
HouZQZhangZXXuZHZhangHTongZFLengYS, The stability of insulin-loaded polybutylcyanoacrylate nanoparticles in an oily medium and the hypoglycemic effect in diabetic rats. Yao Xue Xue Bao.2005;40 (1): 57–64.
83.
FossACGotoTMorishitaMPeppasNA, Development of acrylic-based copolymers for oral insulin delivery. Eur J Pharm Biopharm.2004;57 (2): 163–9.
84.
SajeeshSSharmaC P. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm.2006;325 (1–2): 147–54.
85.
JungTKammWBreitenbachAKaiserlingEXiaoJXKisselT.Biodegradable nanoparticles for oral delivery of peptides: Is there a role for polymers to affect mucosal uptake?Eur J Pharm Biopharm.2000;50 (1): 147–60.
86.
DamgeCReisCPMaincentP.Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv.2008;5 (1): 45–68.
87.
FontePNogueiraTGehmCFerreiraDSarmentoB.Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv Transl Res.2011;1: 299–308.
88.
AttiviDWehrlePUbrichNDamgeCHoffmanMMaincentP. Formulation of insulin-loaded polymeric nanoparticles using response surface methodology. Drug Dev Ind Pharm.2005;31 (2): 179–89.
89.
RamachandranRPaulWSharmaCP, Synthesis and characterization of PEGylated calcium phosphate nanoparticles for oral insulin delivery. J Biomed Mater Res B Appl Biomater.2009;88 (1): 41–8.
90.
WoitiskiCBNeufeldRJVeigaFCarvalhoRAFigueiredoIVPharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur J Pharm Sci.2010;41 (3–4): 556–63.
91.
ZhangXSunMZhengACaoDBiYSunJ.Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci.2012;45 (5): 632–8.
92.
PeppasNAKavimandanNJ, Nanoscale analysis of protein and peptide absorption: Insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. Eur J Pharm Sci.2006;29 (3–4): 183–97.
93.
MillottiGPereraGViglCPicklKSinnerFMBernkop-SchnurchA.The use of chitosan-6-mercaptonicotinic acid nanoparticles for oral peptide drug delivery. Drug Deliv.2011;18 (3): 190–7.
94.
SalmanHHGamazoCCampaneroMAIracheJM, Bioadhesive mannosylated nanoparticles for oral drug delivery. J Nanosci Nanotechnol.2006;6 (9–10): 3203–9.
95.
HossainSChowdhuryEHAkaikeT.Nanoparticles and toxicity in therapeutic delivery: The ongoing debate. Ther Deliv.2011;2 (2): 125–32.
96.
FlorenceAT, Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target.2004;12 (2): 65–70.
97.
GoldbergMGomez-OrellanaI. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov.2003;2 (4): 289–95.
98.
GowthamarajanKKulkarniG.Oral insulin: Fact or fction? Possibilities of achieving oral delivery for insulin. Resonance.2003;8 (5): 38–46.
99.
ReisC PVeigaFNunesPSoaresAFLaranjeiraTCarvalhoRJonesJFigueiredoI VRibeiroAJCabritaAM, Toxicological in vivo studies of an oral insulin nanosystem. Toxicol Lett2007;172Suppl 1: S90.
SonajeKLinYHJuangJHWeySPChenCTSungHW, In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials.2009;30 (12): 2329–39.
102.
YinLDingJHeCCuiLTangCYinC.Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials.2009;30 (29): 5691–700.
103.
ZhengAPCaoDYBiYQCuiXZhangXYSunJX, Evaluation of bioadhesion and toxicity of chitosan-coated insulin-loaded poly(lactide-co-glycolide) nanoparticles. Chin Pharm J.2010;45: 1005–10.
